Global Artificial Pancreas Device System (APDS) Market: Share, Size, Growth, Opportunity and Forecast 2020-2027

 

Patients with type 1 diabetes (T1D) may find it challenging to administer insulin on a regular basis. By taking the place of painful insulin delivery tools like needles and syringes, technology like insulin pumps, pens, and jet injectors have reduced the stress associated with controlling diabetes. Additionally, companies like Tandem Diabetes Care, Inc., Johnson & Johnson, and the Juvenile Diabetes Research Foundation (JDRF) have worked together to develop cutting-edge insulin and glucose monitoring systems and equipment.

Two different types of diabetes monitoring equipment are included in Artificial Pancreas Device System (APDS) Market: an insulin infusion pump and a continuous glucose monitor (CGM). a glucose meter or other blood glucose monitoring device that is used to calibrate the CGM.

Two different types of diabetes monitoring equipment are included in Artificial Pancreas Device System (APDS) Market: an insulin infusion pump and a continuous glucose monitor (CGM). a glucose meter or other blood glucose monitoring device that is used to calibrate the CGM. By automatically stopping insulin treatment for up to two hours when a person's blood glucose level falls below a predetermined level, these devices are designed to decrease hypoglycemia excursions.

The increased demand for the Artificial Pancreas Device System (APDS) Market for glycemic control, intense R&D efforts by industry participants, and the rising prevalence of diabetes are the key reasons propelling the industry's expansion. Patients with diabetes are controlled by artificial pancreas device systems (APDS), and industry participants are always researching new methods for better diabetes management. Because they are less invasive, these devices are widely used by the patient population. The market's expansion is mostly attributed to the rising elderly population, rising diabetes incidence, and rising obesity prevalence.

Key Players

Medtronic Plc., Medtrum Technologies Inc., Tandem Diabetes Care, Inc., Johnson & Johnson, Beta Bionics, Inc., Bigfoot Biomedical, Insulet Corporation, Pancreum, Inc., TypeZero Technologies, Inc., DreaMed Diabetes Ltd, and Inreda Diabetic BV are some of the major companies competing in the artificial pancreas device system (APDS) market.